Open AccessImmune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1–3, 2010
Author(s) -
Haaheim Lars R.,
Katz Jacqueline M.
Publication year - 2011
Publication title -
influenza and other respiratory viruses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.743
H-Index - 57
eISSN - 1750-2659
pISSN - 1750-2640
DOI - 10.1111/j.1750-2659.2011.00242.x
Subject(s) - licensure , pandemic , live attenuated influenza vaccine , miami , influenza a virus subtype h5n1 , virology , immunogenicity , influenza vaccine , vaccination , medicine , public health , immunology , immune system , virus , covid-19 , infectious disease (medical specialty) , disease , environmental science , nursing , pathology , soil science
Please cite this paper as: Haaheim and Katz (2011) Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1–3, 2010. Influenza and Other Respiratory Viruses 5(4), 288–295 The emergence of a novel swine‐origin pandemic influenza virus in 2009, together with the continuing circulation of highly pathogenic avian H5N1 viruses and the urgent global need to produce effective vaccines against such public health threats, has prompted a renewed interest in improving our understanding of the immune correlates of protection against influenza. As new influenza vaccine technologies, including non‐HA based approaches and novel production platforms are developed and undergo clinical evaluation, it has become clear that existing immune correlates such as serum hemagglutination‐inhibition antibodies may be unsuitable to estimate vaccine immunogenicity and protective efficacy of such vaccines. This International Society for Influenza and other Respiratory Virus Diseases (ISIRV) sponsored international meeting held in Miami, Florida USA on March 1–3, 2010, brought together scientists from industry, academia, and government agencies that develop and evaluate seasonal and pandemic influenza vaccines and scientists from regulatory authorities that approve them, to identify approaches to develop expanded immune correlates of protection to aid in vaccine licensure.